CIRM Funded Clinical Trials

Induction of Tolerance by Combinatorial Therapy w/ Donor Stem Cells and Expanded Recipient Treg cells in HLA-mismatched Kidney Transplant Recipients


Everett Meyer
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$11,955,585
Trial Sponsor:
Stanford University
Trial Stage: 
Phase 1
Trial Status: 
Not yet recruiting
Targeted Enrollment:
22
ClinicalTrials.gov ID:
Details: 

Dr. Meyer, and his team at Stanford University, will use a combination of healthy donor stem cells and the patient’s own regulatory T cells (Tregs), to train the patient’s immune system to accept the transplanted kidney and eliminate the need for immunosuppressive drugs.

The initial group targeted in this clinical trial are people with what are called HLA-mismatched kidneys. This is where the donor and recipient do not share the same human leukocyte antigens (HLAs), proteins located on the surface of immune cells and other cells in the body. Around 50 percent of patients with HLA-mismatched transplants experience rejection of the organ.

The goal is “one kidney for life” off drugs with safety for all patients. The team hope that be eliminating the needs for immunosuppressive drugs the health of the patients will improve due to reduction in side effects associated with these drugs, and reduced likelihood of the body rejecting the transplanted organ.